| |
original article |
Date |
Title |
Authors All Authors |
| 1 |
[GO] |
2025―Dec―23 |
Pharmacokinetic assessment of two IgG1 kappa monoclonal antibodies neutralising the SARS-CoV-2: A study in Syrian hamsters and ICR CD1 outbred mice |
T. N. Barybina, N. M. Faustova, M. V. Karlina, V. M. Kosman, P. P. Solodkov, S. V. Kulemzin, et al. (+2) M. N. Makarova, V. G. Makarov |
| 2 |
[GO] |
2024―Oct―02 |
The problem of SARS-CoV-2 virus resistance to direct-acting antivirals |
E. L. Gasich, E. N. Krotkova, A. D. Kasko, K. Yu. Bulda, A. G. Krasko, E. A. Dorofeeva, I. A. Karpov |
| 3 |
[GO] |
2023―Dec―20 |
Evaluation of humoral immune responses of experimental animals to the recombinant SARS-CoV-2 spike ectodomain with the ISCOM adjuvant |
V. A. Evseenko, A. V. Zaykovskaya, A. S. Gudymo, O. S. Taranov, S. E. Olkin, A. R. Imatdinov, et al. (+7) E. Yu. Prudnikova, N. V. Danilchenko, I. S. Shulgina, M. N. Kosenko, E. I. Danilenko, S. A. Pyankov, A. B. Ryzhikov |
| 4 |
[GO] |
2023―Oct―04 |
Comparative safety evaluation of intranasal and intramuscular immunisation with Ad26 and Ad5-vectored vaccines to prevent coronavirus infection |
E. V. Zuev, O. L. Evdokimova, O. A. Markova, I. A. Korotkevich, T. V. Grigorieva, R. A. Khamitov |
| 5 |
[GO] |
2023―Oct―04 |
<i>In vitro</i> antiviral activity of a double-stranded RNA sodium salt-based medicinal product against SARS-CoV-2 |
G. M. Ignatyev, E. Yu. Shustova, E. A. Rogozhina, P. A. Belyi, K. Ya. Zaslavskaya, V. A. Merkulov |
| 6 |
[GO] |
2022―Dec―30 |
Preclinical studies of antiviral activity of the RPH-137 fusion protein and molnupiravir against COVID-19 |
E. V. Shipaeva, O. V. Filon, A. V. Zintchenko, G. A. Shipunov, A. A. Dmitrieva, M. S. Lemak, et al. (+9) S. A. Grishin, E. I. Trofimets, K. L. Kryshen, L. I. Kozlovskaya, A. S. Lunin, V. D. Apolokhov, S. F. Barbashov, Ya. V. Lavrovsky, M. Yu. Samsonov |
| 7 |
[GO] |
2022―Dec―30 |
Levilimab clinical efficacy for interleukin-6 receptor inhibition in COVID-19 and its potential for treating cytokine release syndrome of other aetiologies |
N. V. Lomakin, B. A. Bakirov, G. H. Musaev, V. V. Popov, E. A. Smolyarchuk, Yu. N. Linkova, et al. (+6) D. V. Bogdan, A. V. Eremeeva, P. S. Pukhtinskaia, M. A. Morozova, A. V. Zinkina-Orikhan, A. A. Lutckii |
| 8 |
[GO] |
2022―Dec―30 |
Environmental, biological and social factors contributing to new rises in COVID-19 morbidity in Russia |
T. E. Sizikova, V. N. Lebedev, S. V. Borisevich |
| 9 |
[GO] |
2022―Dec―30 |
Aspects and issues of marketing authorisation and use of medicinal products for COVID-19 prevention during the pandemic |
A. A. Soldatov, D. V. Gorenkov, V. A. Merkulov, V. P. Bondarev |
| 10 |
[GO] |
2022―Dec―30 |
The use of quantitative enzyme-linked immunosorbent assay for the determination of S-antigen concentration in whole-virion inactivated adsorbed coronavirus vaccines |
A. S. Oksanich, A. G. Krasko, T. G. Samartseva, E. L. Gasich, G. M. Ignatyev |
| 11 |
[GO] |
2022―Dec―30 |
Selection of a SARS-CoV-2 antibody quantification method and development of an antibody reference standard for ELISA to test immunoglobulin preparations |
T. I. Smolyanova, A. M. Nikolaeva, T. V. Vyaznikova, A. V. Ivanov, O. V. Belyakova, E. I. Sakanyan |
| 12 |
[GO] |
2022―Dec―30 |
An experience of scaling and intensifying the industrial production of the Gam-COVID-Vac vector adenovirus vaccine in the limiting conditions of the pandemic |
A. N. Morozov, I. R. Yakhin, N. V. Stratonova, M. V. Kutskir, D. A. Poteryaev, R. A. Khamitov |
| 13 |
[GO] |
2021―Dec―22 |
Comparative analysis of existing platforms for the development of vaccines against dangerous and extremely dangerous viral infections with pandemic potential |
G. G. Onishchenko, T. E. Sizikova, V. N. Lebedev, S. V. Borisevich |
| 14 |
[GO] |
2021―Oct―04 |
Assessment of T-cell immunity to SARS-CoV-2 in COVID-19 convalescents and vaccinated subjects, using TigraTest® SARS-CoV-2 ELISPOT kit |
D. A. Poteryaev, S. G. Abbasova, P. E. Ignatyeva, O. M. Strizhakova, S. V. Kolesnik, R. A. Khamitov |
| 15 |
[GO] |
2021―Oct―04 |
Comparative characteristics of COVID-19 vaccines used for mass immunisation |
G. G. Onishchenko, T. E. Sizikova, V. N. Lebedev, S. V. Borisevich |
| 16 |
[GO] |
2020―Dec―15 |
Analysis of Promising Approaches to COVID-19 Vaccine Development |
G. G. Onishchenko, T. E. Sizikova, V. N. Lebedev, S. V. Borisevich |
| 17 |
[GO] |
2020―Dec―15 |
Russian and International Regulatory Recommendations for the Development and Marketing Authorisation of COVID-19 Vaccines in the Context of the Pandemic |
A. A. Soldatov, Zh. I. Avdeeva, V. P. Bondarev, V. A. Merkulov, V. D. Mosyagin, V. B. Ivanov, et al. (+2) D. V. Gorenkov, L. M. Khantimirova |
| 18 |
[GO] |
2020―Sep―18 |
Prospects for Using the ELISPOT Technological Platform as Part of Anti-Epidemic Measures Against the New Coronavirus Infection COVID-19 |
D. A. Poteryaev, R. A. Khamitov, G. A. Efimov, A. M. Shuster |
| 19 |
[GO] |
2020―Mar―26 |
An Outbreak of a New Infectious Disease COVID-19: β-coronaviruses as a Threat to Global Healthcare |
D. V. Gorenkov, L. M. Khantimirova, V. A. Shevtsov, A. V. Rukavishnikov, V. A. Merkulov, Yu. V. Olefir |
